title: Effects of sulindac and indomethacin on renal prostaglandin synthesis.
abstract: We compared the effects of sulindac and indomethacin, the effects of two nonsteroidal anti-inflammatory drugs, on renal prostaglandin synthesis and renal function. Sulindac, 200 mg twice daily, indomethacin, 25 mg four times a day, or placebo were taken by 15 normal female subjects (five in each of three treatment groups). Indomethacin decreased renal excretion of prostaglandins PGE2, PGF2 alpha, and 6-keto-PGF1 alpha, but sulindac and placebo had no effect on renal prostaglandin excretion. Concomitant with the reduction of renal prostaglandin synthesis in the indomethacin group, sodium and chloride excretion decreased; sulindac and placebo had no discernible effects on urine electrolytes. Extrarenal cyclooxygenase activity, as assessed by platelet thromboxane beta 2 release, was inhibited by both sulindac and indomethacin. Plasma renin activity and plasma aldosterone levels fell in all groups as a result of positive sodium balance, but the decrements of aldosterone were greater after indomethacin and sulindac. None of the treatments altered glomerular filtration rate or renal plasma flow in these normal women. We conclude that in normal women renal prostaglandin synthesis and prostaglandin-dependent tubular functions such as Na and Cl reabsorption are relatively unaffected by doses of sulindac (200 mg twice daily) that inhibit nonrenal cyclooxygenase. This may reflect the capacity of oxidative enzymes in the kidney to convert the active sulfide metabolite of sulindac to the inactive prodrug sulindac sulfoxide.
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis* / Q000652:urine; D000293:Adolescent; D000328:Adult; D002712:Chlorides / Q000652:urine; D004311:Double-Blind Method; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007192:Indenes / Q000494:pharmacology*; D007213:Indomethacin / Q000097:blood / Q000494:pharmacology* / Q000652:urine; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D010974:Platelet Aggregation; D011188:Potassium / Q000652:urine; D011446:Prospective Studies; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011458:Prostaglandins E / Q000096:biosynthesis* / Q000652:urine; D011460:Prostaglandins F / Q000096:biosynthesis* / Q000652:urine; D012964:Sodium / Q000652:urine; D013467:Sulindac / Q000097:blood / Q000494:pharmacology* / Q000652:urine; D013929:Thromboxane B2 / Q000097:blood
chemical_list: D002712:Chlorides; D007192:Indenes; D011458:Prostaglandins E; D011460:Prostaglandins F; D013467:Sulindac; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D012964:Sodium; D011451:Prostaglandin-Endoperoxide Synthases; D011188:Potassium; D007213:Indomethacin